Patent Upheld On Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company Abilify Schizophrenia Medication
Bloomberg -- Bristol-Myers Squibb Co. partner Otsuka Pharmaceutical Co. won a court ruling that will prevent generic versions of the schizophrenia treatment Abilify from entering the U.S. market until April 2015.